| Variables |
All patients
(n=52) |
Coronary collateral circulation |
p |
Well developed
(n=27)
48.1% |
Poor developed
(n=25)
51.9% |
| ACE inhibitors/ARB, n (%) |
10 (19.2) |
7 (25.9) |
3 (12) |
0.296 |
| Beta blocker, n (%) |
12 (23.1) |
6 (22.2) |
6 (24) |
1.000 |
| Statin, n (%) |
17 (32.7) |
6 (22.2) |
11 (44) |
0.169 |
| Fibrate, n (%) |
6 (11.5) |
3 (11.1) |
3 (12) |
1.000 |
| Nitrate, n (%) |
5 (9.6) |
4 (14.8) |
1 (4) |
0.352 |
| Calcium channel blockers, n (%) |
5 (9.6) |
3 (11.1) |
2 (8) |
1.000 |
| Acetyl salicylic acid, n (%) |
24 (46.2) |
11 (40.7) |
13 (52) |
0.592 |
|
